The activity of anandamide at vanilloid VR1 receptors requires facilitated transport across the cell membrane and is limited by intracellular metabolism.
The endogenous ligand of CB(1) cannabinoid receptors, anandamide, is also a full agonist at vanilloid VR1 receptors for capsaicin and resiniferatoxin, thereby causing an increase in cytosolic Ca(2+) concentration in human VR1-overexpressing (hVR1-HEK) cells. Two selective inhibitors of anandamide facilitated transport into cells, VDM11 and VDM13, and two inhibitors of anandamide enzymatic hydrolysis, phenylmethylsulfonyl fluoride and methylarachidonoyl fluorophosphonate, inhibited and enhanced, respectively, the VR1-mediated effect of anandamide, but not of resiniferatoxin or capsaicin. The nitric oxide donor, sodium nitroprusside, known to stimulate anandamide transport, enhanced anandamide effect on the cytosolic Ca(2+) concentration. Accordingly, hVR1-HEK cells contain an anandamide membrane transporter inhibited by VDM11 and VDM13 and activated by sodium nitroprusside, and an anandamide hydrolase activity sensitive to phenylmethylsulfonyl fluoride and methylarachidonoyl fluorophosphonate, and a fatty acid amide hydrolase transcript. These findings suggest the following. (i) Anandamide activates VR1 receptors by acting at an intracellular site. (ii) Degradation by fatty acid amide hydrolase limits anandamide activity on VR1; and (iii) the anandamide membrane transporter inhibitors can be used to distinguish between CB(1) or VR1 receptor-mediated actions of anandamide. By contrast, the CB(1) receptor antagonist SR141716A inhibited also the VR1-mediated effect of anandamide and capsaicin on cytosolic Ca(2+) concentration, although at concentrations higher than those required for CB(1) antagonism.
De Petrocellis
L
L
Endocannabinoid Research Group, Istituto per la Chimica di Molecole di Interesse Biologico and the Istituto di Cibernetica, C. N. R., Via Toiano 6, 80072, Arco Felice, Napoli, Italy.
Bisogno
T
T
Maccarrone
M
M
Davis
J B
JB
Finazzi-Agro
A
A
Di Marzo
V
V
D001095:Arachidonic Acids / Q000493:pharmacokinetics / Q000494:pharmacology*; D001692:Biological Transport / Q000187:drug effects; D002118:Calcium / Q000378:metabolism; D002186:Cannabinoids / Q000493:pharmacokinetics / Q000494:pharmacology*; D002211:Capsaicin / Q000494:pharmacology; D002460:Cell Line; D002462:Cell Membrane / Q000187:drug effects / Q000502:physiology*; D003600:Cytosol / Q000378:metabolism; D004224:Diterpenes / Q000494:pharmacology; D063388:Endocannabinoids; D004791:Enzyme Inhibitors / Q000494:pharmacology; D006801:Humans; D007700:Kinetics; D009599:Nitroprusside / Q000494:pharmacology; D063065:Organophosphonates / Q000494:pharmacology; D053284:Polyunsaturated Alkamides; D011955:Receptors, Drug / Q000187:drug effects / Q000235:genetics / Q000502:physiology*; D011994:Recombinant Proteins / Q000187:drug effects / Q000378:metabolism; D020133:Reverse Transcriptase Polymerase Chain Reaction; D014162:Transfection
D001095:Arachidonic Acids; D002186:Cannabinoids; D004224:Diterpenes; D063388:Endocannabinoids; D004791:Enzyme Inhibitors; C094147:N-(2-(4-hydroxyphenyl)ethyl)arachidonamide; D063065:Organophosphonates; D053284:Polyunsaturated Alkamides; D011955:Receptors, Drug; D011994:Recombinant Proteins; C104810:methyl arachidonylfluorophosphonate; D009599:Nitroprusside; C024353:resiniferatoxin; D002211:Capsaicin; D002118:Calcium; C078814:anandamide